PRQR - プロキュ―ア―ル・セラピュ―ティクス (ProQR Therapeutics N.V.) プロキュ―ア―ル・セラピュ―ティクス

 PRQRのチャート


 PRQRの企業情報

symbol PRQR
会社名 ProQR Therapeutics N.V. (プロキュ―ア―ル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ProQR Therapeutics N.V. (ProQR) formerly ProQR Therapeutics B.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA or Messenger Ribonucleic Acid (mRNA) that is transcribed from a mutated gene in order to restore the expression and function of normal or wild-type protein. Its product candidates include QR-010 an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF) QR-110 an oligonucleotide for the treatment of Leber’s congenital amaurosis (LCA) and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).   プロキュ―ア―ル・セラピュ―ティクスは、深刻な遺伝子疾患の治療や開発を行うオランダのバイオ医薬品企業。欠陥のあるメッセンジャ―RNAを特異的に標的・修復する治療候補を設計する。全世界に7万から10万の患者がいる嚢胞性線維症の治療のための病態修飾療法の開発に焦点を当てる。   
本社所在地 Zernikedreef 9 Leiden 2333 CK NLD
代表者氏名 Daniel De Boer ダニエル・デ・ボア
代表者役職名 Founding Chief Executive Officer
電話番号 +31 854-89-4932
設立年月日 40940
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 130人
url www.proqr-tx.com
nasdaq_url https://www.nasdaq.com/symbol/prqr
adr_tso
EBITDA EBITDA(百万ドル) -42.47853
終値(lastsale) 17.75
時価総額(marketcap) 566839789
時価総額 時価総額(百万ドル) 725.42930
売上高 売上高(百万ドル) 2.65606
企業価値(EV) 企業価値(EV)(百万ドル) 696.71117
当期純利益 当期純利益(百万ドル) -45.83228
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ProQR Therapeutics NV revenues increased from EUR658K to EUR1.5M. Net loss decreased 18% to EUR18M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development costs decrease of 12% to EUR13.7M (expense) Finance income and expense decrease of 66% to EUR590K (expense).

 PRQRのテクニカル分析


 PRQRのニュース

   ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact  2021/05/04 13:35:06 Benzinga
Yarrow Biotechnology Inc , a newly created company by RTW Investments LP , has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: PRQR ) antisense oligonucleotide technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Under the terms of the agreement, … Full story available on Benzinga.com
   Why PRQR Stock And APOP Stock Are Popping Off Today  2021/03/25 16:18:38 Benzinga
ProQR Therapeutics NV (NASDAQ: PRQR ) shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially. ProQR is a biopharmaceutical … Full story available on Benzinga.com
   ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference  2020/12/18 12:00:00 GlobeNewswire
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated…
   ProQR Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/04 20:53:00 Stock Market Daily
ProQR Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   Why PRQR Stock And APOP Stock Are Popping Off Today  2021/03/25 16:18:38 Benzinga
ProQR Therapeutics NV (NASDAQ: PRQR ) shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially. ProQR is a biopharmaceutical … Full story available on Benzinga.com
   ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference  2020/12/18 12:00:00 GlobeNewswire
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated…
   ProQR Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/04 20:53:00 Stock Market Daily
ProQR Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs  2020/10/16 11:15:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Kronos Bio Inc (NASDAQ: KRON ) (IPOed Friday) Larimar Therapeutics Inc (NASDAQ: LRMR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Twist Bioscience Corp (NASDAQ: TWST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 15) ADC Therapeutics SA (NYSE: ADCT ) Alector Inc (NASDAQ: ALEC ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aziyo Biologics Inc (NASDAQ: AZYO ) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq Wednesday) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Dyne Therapeutics Inc (NASDAQ: DYN ) Pandion Therapeutics Inc (NASDAQ: PAND ) ProQR Therapeutics NV (NASDAQ: PRQR ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) (provided a strategic and corporate update) Uniqure NV (NASDAQ: QURE ) Stocks In Focus Zogenix Presents Data Showing Durability of Response For Seizure Drug Zogenix, Inc. (NASDAQ: ZGNX ) released interim data from open-label extension trial, showing substantial seizure reductions were maintained when treated with Fintepla oral solution for up to two years.
   ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference  2020/12/18 12:00:00 GlobeNewswire
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated…
   ProQR Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/04 20:53:00 Stock Market Daily
ProQR Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs  2020/10/16 11:15:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Kronos Bio Inc (NASDAQ: KRON ) (IPOed Friday) Larimar Therapeutics Inc (NASDAQ: LRMR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Twist Bioscience Corp (NASDAQ: TWST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 15) ADC Therapeutics SA (NYSE: ADCT ) Alector Inc (NASDAQ: ALEC ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aziyo Biologics Inc (NASDAQ: AZYO ) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq Wednesday) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Dyne Therapeutics Inc (NASDAQ: DYN ) Pandion Therapeutics Inc (NASDAQ: PAND ) ProQR Therapeutics NV (NASDAQ: PRQR ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) (provided a strategic and corporate update) Uniqure NV (NASDAQ: QURE ) Stocks In Focus Zogenix Presents Data Showing Durability of Response For Seizure Drug Zogenix, Inc. (NASDAQ: ZGNX ) released interim data from open-label extension trial, showing substantial seizure reductions were maintained when treated with Fintepla oral solution for up to two years.
   Usher Syndrome Type 2 Treatment Market Outlook and Forecast Report By ProQR Therapeutics, Editas Medicine, Nobelpharma Co., Ltd, Sensorion, Advanced Bionics AG  2020/09/30 19:11:31 OpenPR
The company profiles of all the key players and brands that are dominating the Usher Syndrome Type 2 Treatment Market have been taken into consideration here. The report has wide-ranging and comprehensive market insights which are based on business intelligence. This Global Usher

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 プロキュ―ア―ル・セラピュ―ティクス PRQR ProQR Therapeutics N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)